Trial 0C-23-16


A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Mary Ordaz, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Niranjan Bhatt, D.M., Negeen Izadian, Coordinator, Sreebharathy Venkatesh, D.M., Clara Karam, D.M., Sana Mutalib, Coordinator, Andrew Zeng, Coordinator, Thomas Won, Coordinator, Bomi Choi, Coordinator, Brianna Olea, Coordinator, Marc Cruz, D.M., Stephanie Kim, Coordinator, Maura Fernandez, D.M., Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M., Teshia Bustos, Coordinator, Alexandra Artura, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.